Loading…
Celcuity Inc.
Celcuity Inc. (CELC) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Minneapolis, United States and has 155 employees. The company is worth $3.21B. The share price is 56.6% below its 52-week high of $151.02. 2 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $68.1M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +274.7% over 5Y.
today you would have $3,125.97▲ +212.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $99.74 | $13.09 | $14.57 | $14.01 | $13.19 | $9.16 | $10.64 | $23.99 | $18.95 | |
| P/B | 5.7x | 47.9x | 4.3x | 3.2x | 2.3x | 2.9x | 8.1x | 5.7x | 9.7x | 6.1x |
| EPS | -$3.79 | -$2.83 | -$2.69 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| WRBYWarby Parker Inc. | $25.67 | 427.8x | 8.1x | 0.00% | 2.06% | $3.17B |
| PLSEPulse Biosciences Inc | $44.43 | — | 31.6x | 0.00% | -78.49% | $3.17B |
| VKTXViking Therapeutics, Inc. | $25.83 | — | 7.4x | 0.00% | -88.85% | $3.28B |
| ELVNEnliven Therapeutics, Inc. | $41.93 |
| -$2.64 |
| -$2.21 |
| -$0.92 |
| -$0.72 |
| -$0.74 |
| -$0.84 |
| ROE | -43.09% | -176.06% | -96.68% | -45.63% | -30.18% | -43.09% | -80.96% | -38.14% | -29.51% | -19.92% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 3.4x |
| 0.00% |
| -15.31% |
| $3.07B |
| TARSTarsus Pharmaceuticals, Inc. | $72.08 | — | 9.0x | 0.00% | -13.68% | $3.37B |
| ATRCAtriCure, Inc. | $59.30 | 282.4x | 5.8x | 0.00% | 2.15% | $3.02B |